Status:
RECRUITING
Analysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy
Lead Sponsor:
GCS Ramsay Santé pour l'Enseignement et la Recherche
Conditions:
Cardiac Amyloidosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Recently, treatment with tafamidis in patients with cardiac ATTR lead to a significant reduction in mortality. The Perugini score is commonly used on planar bone scans to differentiate cardiac ATTR fr...
Detailed Description
Cardiac amyloidosis is a cause of restrictive cardiomyopathy with preserved ejection fraction associated with amyloid fibrils deposits in the myocardium. Two types of amyloid commonly infiltrate the h...
Eligibility Criteria
Inclusion
- Patient, male or female, over 18 years of age
- Patient diagnosed with transthyretin cardiac amyloidosis confirmed by scintigraphy
- Patient with signed consent
Exclusion
- Patients with systemic AL amyloidosis
- Protected patient : major under guardianship, tutorship or other legal protection, deprived of liberty by judicial or administrative decision
- Pregnant or breastfeeding woman
Key Trial Info
Start Date :
February 25 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04849754
Start Date
February 25 2021
End Date
December 1 2025
Last Update
April 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital privé Le Bois
Lille, France, 59000